Table 1.
Demographic, clinical, and pathologic characteristics of patients undergoing radical prostatectomy
| Spinal (n=1,166) | General (n=798) | P-value† | |
|---|---|---|---|
|
| |||
| Median age (IQR) | 58 (54–62) | 58 (54–63) | 0.127 (rank-sum) |
|
| |||
| Median BMI, kg/m2 (IQR)‡ | 26.6 (24.8–28.9) | 26.9 (25.1–29.6) | 0.022 (rank-sum) |
|
| |||
| No. clinical stage (%)* | |||
|
| |||
| T1 | 918 (78.9) | 648 (81.6) | 0.067 |
| T2 | 242 (20.8) | 140 (17.6) | |
| T3 | 3 (0.3) | 6 (0.8) | |
|
| |||
| Median preop PSA, ng/ml (IQR) | 5.5 (4.2 – 7.6) | 5.4 (4.1 – 7.8) | 0.329 (t-test) |
|
| |||
| No. biopsy Gleason sum (%) | |||
|
| |||
| 5–6 | 934 (80.1) | 573 (71.8) | < 0.001 |
| 7 (3+4) | 154 (13.2) | 143 (17.9) | |
| 7 (4+3) | 57 (4.9) | 50 (6.3) | |
| 8–10 | 21 (1.8) | 32 (4.0) | |
|
| |||
| No. positive cores (%)¶ | |||
| 1 | 242 (41.1) | 195 (34.2) | 0.020 |
| 2 | 139 (23.6) | 132 (23.1) | |
| 3 or more | 208 (35.3) | 244 (42.7) | |
|
| |||
| No. max percent core involvement (%)§ | |||
| 1–5 | 33 (6.4) | 26 (5.1) | 0.004 |
| 6–50 | 309 (59.4) | 255 (50.4) | |
| 51–100 | 178 (34.2) | 225 (44.5) | |
|
| |||
| No. pathological Gleason sum (%) | |||
|
| |||
| 5–6 | 791 (67.8) | 492 (61.7) | 0.005 |
| 7 (3+4) | 248 (21.3) | 178 (22.3) | |
| 7 (4+3) | 73 (6.3) | 75 (9.4) | |
| 8–10 | 54 (4.6) | 53 (6.6) | |
|
| |||
| No. pathologic stage (%) | |||
|
| |||
| pT2 (organ confined) | 869 (74.5) | 572 (71.7) | 0.162 |
| pT3a/b (extraprostatic extension) | 254 (21.8) | 182 (22.8) | |
| pT3c (seminal vesicle invasion) | 33 (2.8) | 30 (3.8) | |
| Lymph node-positive | 10 (0.9) | 14 (1.7) | |
|
| |||
| No. with(out) biochemical recurrence (%) | |||
|
| |||
| No recurrence | 1041 (89.3) | 684 (85.7) | 0.018 |
| Recurrence | 125 (10.7) | 114 (14.3) | |
|
| |||
| Median ASA (IQR) | 2 (2 – 2) | 2 (2 – 2) | 0.147 (rank-sum) |
|
| |||
| Median anesthesia time, min (IQR) | 150 (136–165) | 144 (125–165) | < 0.001 (t-test) |
|
| |||
| Median surgery time, min (IQR) | 112 (99 – 125) | 107 (91 – 121) | 0.005 (t-test) |
|
| |||
| Median follow-up time, years (IQR) | 4 (2 – 9) | 5 (3 – 7) | 0.505 (t-test) |
†
Chi-square test except where noted.
‡
In 1,143 and 503 men who received spinal and general anesthesia, respectively.
*
In 1,163 and 794 men who received spinal and general anesthesia, respectively.
¶
In 589 and 571 men who received spinal and general anesthesia, respectively.
§
In 520 and 506 men who received spinal and general anesthesia, respectively.